Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYDRAZID vs PASKALIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
Treatment of active tuberculosis (in combination with other antituberculous agents),Prophylaxis of tuberculosis in high-risk individuals
Treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with other antituberculosis agents
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism primarily via N-acetyltransferase 2 (NAT2) to acetylisoniazid, which is further metabolized to hepatotoxic metabolites.
PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
10-20% bound primarily to albumin; binding is low and clinically insignificant.
98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Vd: 0.6-0.8 L/kg; distributes into total body water, including CSF, pleural fluid, and caseous granulomas.
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity.
Oral: 90-100% (fasting). Food may decrease absorption by 20-50%; take on empty stomach.
Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%.
If GFR < 30 m L/min: administer 200 mg once daily or 300 mg three times weekly. For severe renal impairment (GFR < 10 m L/min) or hemodialysis: 200 mg daily or 300 mg three times weekly, given after dialysis.
GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% (e.g., 150 mg daily). Child-Pugh Class C: reduce dose by 50-75% (e.g., 100-150 mg daily) or consider alternative therapy; monitor liver function closely.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily.
For latent tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 6-9 months. For active tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 2 months, then 15 mg/kg (max 900 mg) orally three times weekly for 4-7 months.
10 mg/kg/day orally in divided doses every 12 hours.
Start at lower end of dosing range (e.g., 200-300 mg daily) due to potential renal impairment; monitor liver function and signs of hepatotoxicity; adjust dose based on creatinine clearance if GFR < 30 m L/min.
Start at 250 mg daily; adjust based on renal function.
Severe and sometimes fatal hepatitis has been reported, even after months of treatment. Risk increases with age, daily alcohol use, and pre-existing liver disease. Monitor liver function tests closely.
None.
Peripheral neuropathy (prevent with pyridoxine), hepatotoxicity, hypersensitivity reactions (e.g., fever, rash), lupus-like syndrome, seizures, optic neuritis, drug interactions (e.g., phenytoin, carbamazepine, disulfiram).
May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy.
Severe hepatic disease, acute liver disease, or previous isoniazid-associated hepatitis; hypersensitivity to isoniazid or any component.
Hypersensitivity to para-aminosalicylic acid or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min)
Isoniazid inhibits monoamine oxidase (MAO) and reduces metabolism of tyramine, leading to hypertensive crisis. Avoid tyramine-rich foods: aged cheeses (cheddar, blue cheese), cured or fermented meats (salami, pepperoni, pickled herring), soy products (tofu, miso, tempeh), sauerkraut, fava beans, tap beers, and red wines. Also avoid foods containing histamine (tuna, mackerel, sauerkraut). Concomitant alcohol consumption increases risk of hepatotoxicity and should be strictly avoided. High-protein meals or dairy may interfere with absorption; maintain consistent timing relative to meals. There is no restriction on carbohydrates or fats.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes). Use of potassium-containing salt substitutes is contraindicated.
Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considered safe during all trimesters; however, due to the risk of hepatotoxicity, monitoring of liver function is recommended, especially in the third trimester. Perinatal exposure increases the risk of neonatal hemorrhage due to vitamin K deficiency, which can be prevented by prophylactic vitamin K administration to the mother.
PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility.
Isoniazid is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. The American Academy of Pediatrics considers it compatible with breastfeeding. However, due to the theoretical risk of hepatotoxicity and peripheral neuropathy in the infant, monitoring of the infant for signs of jaundice, hepatitis, or neuropathy is recommended. The dose to the infant is subtherapeutic (about 0.5-2% of the maternal dose) and is unlikely to cause adverse effects.
Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported.
Standard dosing of isoniazid (300 mg daily or 900 mg twice weekly) is generally recommended during pregnancy. No dose adjustment is required as pregnancy does not significantly alter the pharmacokinetics of isoniazid. However, due to increased hepatic metabolism in pregnancy, some experts recommend monitoring serum drug levels to ensure therapeutic concentrations, though routine monitoring is not standard. Pyridoxine (25-50 mg daily) should be co-administered to prevent peripheral neuropathy in the mother and fetus.
Pregnancy may alter potassium distribution due to increased plasma volume. Dosing should be individualized based on serum potassium levels. No fixed dose adjustment required; titrate to maintain normal potassium levels (3.5-5.0 m Eq/L).
NYDRAZID (isoniazid) is a first-line antitubercular agent. Always prescribe pyridoxine (vitamin B6) 25-50 mg daily to prevent peripheral neuropathy, especially in patients with risk factors like diabetes, alcoholism, malnutrition, or HIV. Monitor liver function tests closely; hepatotoxicity risk increases with age >35, concurrent use of acetaminophen or other hepatotoxic drugs, and pre-existing liver disease. Slow acetylators (genetic) have higher risk of toxicity. Isoniazid can cause bilateral optic neuritis; monitor for visual symptoms. Drug interactions: increases levels of phenytoin, carbamazepine, and theophylline; reduce doses accordingly. Administer on empty stomach (1 hour before or 2 hours after meals) for optimal absorption. In case of overdose, high-dose pyridoxine is antidote (1 g per gram of isoniazid ingested).
PASKALIUM is a potassium-sparing diuretic used for hypertension and edema. Monitor serum potassium regularly; avoid in severe renal impairment or hyperkalemia. Coadministration with ACE inhibitors or NSAIDs increases hyperkalemia risk.
Take isoniazid on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Do not drink alcohol while taking this medication; combined with alcohol increases risk of severe liver damage.,Take vitamin B6 (pyridoxine) exactly as prescribed to prevent nerve damage.,Report immediately: dark urine, pale stools, yellowing of skin or eyes, nausea/vomiting, abdominal pain, unusual fatigue (liver toxicity signs).,Report numbness, tingling, or burning in hands/feet; vision changes; rash; or fever.,Avoid foods high in tyramine (aged cheese, cured meats, soy products, tap beer) while taking isoniazid; may cause hypertensive crisis.,Take all doses on schedule; do not skip or stop without consulting provider.,Keep all follow-up appointments for blood tests to monitor liver function.
Take exactly as prescribed; do not skip doses or double up.,Avoid potassium-rich foods and salt substitutes unless directed.,Report muscle weakness, irregular heartbeat, or signs of hyperkalemia.,May cause dizziness; avoid driving until effects known.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYDRAZID vs PASKALIUM, answered by our medical review team.
NYDRAZID is a Antitubercular Agent that works by Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.. PASKALIUM is a Antitubercular Agent that works by PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYDRAZID and PASKALIUM depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYDRAZID is: 300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.. The standard adult dose of PASKALIUM is: PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYDRAZID and PASKALIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYDRAZID is classified as Category C. Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considere. PASKALIUM is classified as Category C. PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.